Concurrent Investment Advisors LLC Has $1.34 Million Stock Position in Boston Scientific Corporation (NYSE:BSX)

Concurrent Investment Advisors LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 36.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,245 shares of the medical equipment provider's stock after purchasing an additional 3,509 shares during the period. Concurrent Investment Advisors LLC's holdings in Boston Scientific were worth $1,336,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in BSX. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG increased its stake in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE increased its stake in shares of Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the last quarter. Proficio Capital Partners LLC increased its stake in shares of Boston Scientific by 40.2% during the 4th quarter. Proficio Capital Partners LLC now owns 5,333 shares of the medical equipment provider's stock worth $476,000 after purchasing an additional 1,528 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC increased its stake in shares of Boston Scientific by 2.3% during the 4th quarter. Ashton Thomas Private Wealth LLC now owns 5,945 shares of the medical equipment provider's stock worth $531,000 after purchasing an additional 136 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent research reports. Robert W. Baird raised their target price on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Needham & Company LLC restated a "buy" rating and issued a $115.00 target price on shares of Boston Scientific in a report on Wednesday, May 28th. Truist Financial upped their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Finally, Royal Bank Of Canada upped their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Twenty-two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $116.09.

Boston Scientific Price Performance

NYSE:BSX traded up $0.55 during mid-day trading on Wednesday, hitting $102.96. The company's stock had a trading volume of 6,241,035 shares, compared to its average volume of 6,674,272. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $152.32 billion, a price-to-earnings ratio of 75.15, a P/E/G ratio of 2.70 and a beta of 0.68. The stock has a fifty day moving average of $103.45 and a 200-day moving average of $100.33.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. Boston Scientific's revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the company earned $0.56 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $19,077,243.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the transaction, the executive vice president owned 18,705 shares in the company, valued at $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 461,970 shares of company stock worth $47,755,193. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.